SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company" or the "Group")

Update On Board Investigation, Interim Results
and Expected Suspension of Trading

·      HY26 results to be delayed until Board Investigation is complete

·      Shares expected to be suspended from 1 April 2026 until HY26 results are published

20 March 2026 - the Board of SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, updates shareholders on the timing for the interim results for the 6 months ended 31 December 2025 ("Interim Results") and the ongoing Board investigation.

As announced on 20 February 2026, the Board appointed FRP Advisory to undertake an independent, forensic review into the matters outlined by the Company on Monday 16 February 2026. Whilst progress is being made, this forensic review is ongoing and accordingly, the Company will not be in a position to announce the Interim Results by 31 March 2026, as required by the AIM Rules for Companies.

Consequently, the Board expects that trading in the Company's ordinary shares will be suspended with effect from 7.30am on 1 April 2026. Trading in the shares is anticipated to resume upon the finalisation of the Board investigation and the publication of the Interim Results.

The Company has a robust cash position of £2.44m as at the close of 19 March 2026 and its businesses are trading on a "business as usual" basis.

The Board will update shareholders on the result of the forensic review and Board investigation as soon as possible.

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

-Ends-

For more information please contact:

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix^®, is based upon discoveries made by the translational dermatology team at the University of Manchester.

The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix^®) and food supplements that harness the gut-skin axis (AxisBiotix™). The cosmetic pillar has a partnership with Croda plc where SkinBiotix^® is being used as an active skin ingredient with the Croda trade name, Zenakine™. The AxisBiotix™ pillar has a range of products targeting the symptoms of inflammatory skin conditions, being sold directly and via Amazon, and on the High Street in selected Superdrug Stores plc stores.

The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skincare and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products. 

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.SkinBioTherapeutics.com.